Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250021/S002

saypha ChiQ

Croma-Pharma GmbH · Decision date Oct 8, 2026

MEDTECHLEDGER EXPLANATIONP250021/S002

What did the FDA approve?

FDA approved the post-approval study (PAS) protocol for the saypha® ChiQ™ dermal implant, supplement S002 to PMA P250021. The decision, dated 2026-10-08, is recorded as an approval under the Normal 180 Day Track with no user fee.

The PAS protocol was submitted to satisfy conditions of approval in the original P250021 approval order. The source statement does not describe the study design, endpoints, enrollment, or timeline. The device is categorized as an implant, dermal, for aesthetic use under product code LMH, with Croma-Pharma GmbH as the applicant.

FDA approval order statement

Approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250021.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
General, Plastic Surgery
Decision date
Oct 8, 2026
FDA change category
Postapproval Study Protocol

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250021/S002
Regulatory pathway
PMA supplement
Product code
LMH
Decision code
APPR
Decision date
Oct 8, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Product code
LMH
FDA device class
3

For the original device and its historical approval scope, see PMA P250021. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250021/S002 received

    Application receipt date recorded by FDA.

  2. P250021/S002 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P250021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250021

Product / regulatory recordCompanyPathwayDecision dateSource
Croma-Pharma GmbHPMA approvalJun 12, 2026FDA
saypha ChiQP250021/S001
Croma-Pharma GmbHPMA supplementOct 7, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
Restylane ContourP140029/S058
Q-Med ABPMA supplementSep 18, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Croma-Pharma GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Industriezeile 6, Leobendorf, 2100

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records